The Bristol-Myers Squibb Company (NYSE:BMY) is going up by 0.45% in today’s trading session, a rise equivalent to 0.21% of the stock’s price from yesterday’s market close. A news came out on 08/12/19 stating that Thinking about trading options or stock in AbbVie, Bristol-Myers Squibb, Goldman Sachs, Johnson & Johnson, or Micron Technology? by WSJ. The lowest point that the shares touched during the trading session was $46.205, while the peak of the day was recorded at a share price of $47.21. BMY finished the previous session at $46.51 according to the data provided by Barchart, while the trading volume was observed to be $4,066,731.
In the 100 days of trading, BMY managed to top a 46.25% Moving average. Additionally, Bristol-Myers Squibb Company shares have achieved a 52-week range between 42.48 and 63.69 alongside 100 days raw stochastic set at 59.69%.
The number of shares outstanding, according to the fundamentals of the company, is set at 1.63B, equal to the value of $76.03B in market capitalization. Financial analysts indicate that BMY shares should be still ranked as a “Outperform”. In the last 30 days, Bristol-Myers Squibb Company shares went down by -2.38%, adding 47.84 to growth in value, on top of a +9.93% boost since 07/12/19.
Bristol-Myers Squibb Company (NYSE:BMY) Analyst’s Estimates
Bristol-Myers Squibb Company (BMY) could record at least $1.05 per share in quarterly earnings in the upcoming report on 10/28/2019, a number that would actually represent an increase of 2.97% YOY.
According to the average analyst rating, Bristol-Myers Squibb Company would be rated as 2.27. Out of 11 different analysts monitoring BMY stock, 3 analysts rate the stock as a BUY, 6 suggest to give the rating of HOLD, 2 indicate that BMY is an OUTPERFORM, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERPERFORM.
On May-28-19, the stock earned a Initiated rating due to a new analyst call from Goldman, while analysts from Argus believe that the stock is set at Hold from Buy, as concluded on May-20-19. Barclays, is still rather wary about the stock, deciding to keep the rating at Overweight as confirmed through a call on May-03-19.
Regardless of the rating, JP Morgan did increase their price to $62 as they are considering target share price analysis. Societe Generale, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on Jan-15-19, giving the stock a Buy from the Sell rating.
BMY Key Ratios To Watch:
Taking in account the profitability of the Company, gross profit margin of +71.25% has been attained, while the operating margin has been recorded at +28.34%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at 14.36%. Beta value of the stock is recorded at 0.69. Additionally, Bristol-Myers Squibb Company is recording price volatility of 2.15% for the period of the last seven days and 2.17% in the last 30 days.
Bristol-Myers Squibb Company (NYSE:BMY) Technical Outlook
For the period of the last 50 days, Bristol-Myers Squibb Company had its Raw Stochastic average set at 59.69% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 78.73%. Stochastic %K for Bristol-Myers Squibb Company, with the last 20 days included, was set at 81.41%, having Stochastic %D topping 87.92%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for Bristol-Myers Squibb Company stocks with recording -21.87% in metrics.
Bristol-Myers Squibb Company Insider Watch:
As far as the position of shares issued by Bristol-Myers Squibb Company (NYSE:BMY) for the period concluded at the market close of 08/12/19, 918 institutional investors increased their positions in BMY shares by 173,076,078, 802 decreased positions by 104,334,610 and 211 institutional investors decided to hold positions at 1,017,337,475. These numbers put the complete list of institutional holdings set at 1,294,748,163 shares, in accordance with filings submitted to the Securities and Exchange Commission. The stock had another 169 institutional investments with 26,061,712 new shares in addition to having 128 institutional investors selling their positions in 7,817,510 shares.